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Abstract
In this paper we investigate the extent to which variable porosity drug-eluting coatings can
provide better control over drug release than coatings where the porosity is constant throughout.
In particular, we aim to establish the potential benefits of replacing a single-layer with a two-
layer coating of identical total thickness and initial drug mass. In our study, what distinguishes
the layers (other than their individual thickness and initial drug loading) is the underlying
microstructure, and in particular the effective porosity and the tortuosity of the material. We
consider the effect on the drug release profile of varying the initial distribution of drug, the
relative thickness of the layers and the relative resistance to diffusion offered by each layer’s
composition. Our results indicate that the contrast in properties of the two layers can be used
as a means of better controlling the release, and that the quantity of drug delivered in the early
stages can be modulated by varying the distribution of drug across the layers. We conclude
that microstructural and loading differences between multi-layer variable porosity coatings can
be used to tune the properties of the coating materials to obtain the desired drug release profile
for a given application.
1 Introduction
The topic of drug delivery is a truly multi-disciplinary research area and has been attracting
the interest of engineers, mathematicians, chemists and life scientists for decades. In particular,
controlled drug delivery has received much attention, particularly concerning the design of tablets
[1, 2, 3] and local drug delivery devices such as stents [4], transdermal patches [5], contact lenses [6]
and orthopaedic implants [7] (Figure 1). Controlled release of drug from each of these vehicles can in
principle be obtained by varying system design parameters. Some of the most common include the
device geometry and materials; the physico-chemical properties of the drug and; the drug loading
configuration. In the case of experimental studies, it is often demonstrated that different drug release
profiles can be obtained by either varying the experimental conditions (e.g. in-vitro versus in-vivo) or
physical delivery system properties, whilst in the case of mathematical and computational modelling,
it is usual for a sensitivity analysis of the underlying model parameters to be conducted, and release
profiles subsequently simulated. Both approaches are useful and indeed can be complementary in the
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Figure 1: Examples of drug-delivery devices for different applications. From left to right: an
orthopaedic implant [8], a coronary stent [9], a transdermal patch [10] and multi-layer tablets [11].
quest for device design optimisation. In the case of tablets, there is a body of literature concerning
multi-layer systems (see e.g. [1, 2, 3]), where the individual layers contain either different drugs or
chemicals, or contrasting material properties from which the same drug or chemical is released in
a bi- or multi-modal fashion. However, the literature concerning multi-layer drug release from the
aforementioned drug delivery devices is lacking somewhat, particularly in relation to mathematical
modelling (see [12] as a rare exception). This will be the focus of the current manuscript.
Much of the present research concerned with such drug-eluting medical devices is focussed on
developing sophisticated computational models which accurately simulate drug release and the sub-
sequent distribution in the biological environment. The complexity of these models is increasing,
with more and more realistic features being accounted for, including accurate 3D geometrical rep-
resentations of the device and anatomical features; anisotropic and spatially-varying drug transport
properties within the body and; complex features such as nonlinear binding reactions. If, on the one
hand, these models are indeed necessary to accurately simulate drug transport within the device
and in the biological environment, on the other hand it is clear that device manufacturers cannot
intervene on the underlying biology. What they can control, however, are the properties of the
device platform. Therefore, in this paper, we take a step back from the fully coupled computational
models (see e.g. [13]) and focus instead solely on the properties of the drug-containing coating.
The drug is typically contained within some durable/biodegradable polymeric coating attached
to the device platform or embedded within a nanoporous structure. The drug release profile depends
on a number of factors including the porosity of the coating or bulk structure; the drug loading
and initial distribution; the physico-chemical properties of the drug (e.g. molecule size, solubility,
etc.) and; the release medium. A certain level of control is required: an excessive amount of drug
delivered too quickly can result in toxicity whilst too little drug will have no therapeutic effect.
However, the most desirable release profile is not always known and may in fact be patient-specific
and therapy-dependent.
Motivated by today’s advances in material fabrication and by the increased capabilities of the
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Figure 2: Example of two adjacent polymer coatings with different microstructural properties.
These were prepared from different concentrations of polymer solutions (0.6% left and 0.8% right)
[14].
miniaturization of structures offered by micro and nanotechnology, we propose variable porosity
multi-layer coatings as an additional means of controlling the drug delivery and tailoring the release
profile to the desired application. Our initial goal is to gain a better understanding of the potential
benefits of replacing a single-layer with a two-layer drug-eluting coating of identical total thickness
and initial drug mass. In our study, what distinguishes the layers (other than their thickness and
initial drug loading) is the underlying microstructure, and in particular the effective porosity and
tortuosity of the material (Figure 2). The structure of the paper is as follows. In Section 2 we
provide the mathematical formulation of the problem and define a suitable non-dimensionalisation.
We then propose, in Section 3, a semi-analytical solution method which makes use of separation of
variables and expresses the solution as a Fourier series. A special case which admits an analytical
solution is also presented. In the penultimate section we provide our results and investigate the
sensitivity of the release profile to variations in the model parameters. Finally, in Section 5, we
provide the conclusions of our study.
2 Mathematical formulation
A drug delivery device typically includes a polymeric matrix coating containing drug which
is in contact with some release medium. The particular geometry of the device varies between
applications, but the drug-eluting coating can usually reasonably be idealised as a slab (layer) of
some thickness L. In Figure 2 we display an example of the situation we wish to model in the
present work: two adjacent coating layers with different microstructural properties. Since the total
thickness of drug-eluting coatings is typically small relative to the lateral coating dimensions, and
the net drug transport is along a single direction, we restrict our attention to a one-dimensional
model (Figure 3). We consider layers 1 and 2 to have thickness L1 and L2, respectively, with
L = L1 + L2 the total coating thickness, which we keep fixed in the following. We represent each
layer of the porous coating as a homogeneous material and define some representative elementary
volume (r.e.v.) of size larger than the pore scale, but smaller than the typical length scale of the
phenomenon. Within the r.e.v., we have solid and void parts. We choose to define all concentrations
as intrinsically averaged variables, that is, averaged with respect to the void volume, rather than
the total r.e.v.
Let c1 and c2 then denote the intrinsic concentrations of drug in layer 1 of constant porosity φ1
and layer 2 of constant porosity φ2, respectively. We further define φei , i = 1, 2 (0 < φ
e
i ≤ φi) as the
effective transport-through porosities, which may be smaller than the overall porosity of each layer
if, for example, there are small inaccessible pores or dead-end pores [15]. Additionally, we directly
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Figure 3: Schematic showing a simplified one-dimensional configuration of drug release from a
medical device coating into a release medium. Two porous layers of different thickness and structure
are faced. Due to an initial difference of drug concentrations between the two layers and the release
medium, a mass flux is established to the right and drug diffuses through the coating and into the
release medium. Figure not to scale.
account for the fact that the molecules may have to travel through an increased path length due
to the circuitous nature of the pores by introducing a tortuosity parameter τi, i = 1, 2. Assuming
that the coating is rapidly wetted and that the drugs are readily soluble, it can be shown that drug
transport satisfies the following diffusion equations
φ1
∂c1
∂t
= De1
∂2c1
∂x2
, −L1 < x < 0, t > 0, (2.1)
φ2
∂c2
∂t
= De2
∂2c2
∂x2
, 0 < x < L2, t > 0, (2.2)
where De1 =
φe1D
w
τ1
and De2 =
φe2D
w
τ2
are the effective diffusion coefficients in each layer and Dw
is the corresponding free diffusion of drug in water [16] . We emphasize that Dw is independent
of the microstructure and that we consider only the case of the same drug in each layer. In this
work we envisage medical implant coatings which release drug through fluid-filled pores only. As
a consequence, we do not consider diffusion in the solid phase, which can be several orders of
magnitude slower than in the liquid phase.
For the sake of generality, we impose a mixed-type condition at both ends:
−De1
∂c1
∂x
= K1c1, x = −L1, t > 0, (2.3)
−De2
∂c2
∂x
= K2c2, x = L2, t > 0, (2.4)
where we may, in principle, choose K1 and K2 to match experimentally measured flux. The above
boundary conditions allow us to explore the two extreme cases of zero flux and infinite sink conditions
(see Section 4). If, for example, the coating is attached to an impermeable device (e.g. a stent) and
drug release is measured under infinite sink conditions, we can let K1 = 0 and K2 →∞.
At the interface between the two layers we impose continuity of flux. To keep the problem
general, this flux accounts for a possible drug partitioning or a non-perfect contact, modelled through
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a mass transfer coefficient P (m/s):
−De1
∂c1
∂x
= P (c1 − c2), x = 0, t > 0, (2.5)
−De1
∂c1
∂x
= −De2
∂c2
∂x
, x = 0, t > 0, (2.6)
We assume that initially the drug is loaded at uniform concentrations c01 and c
0
2 in layers 1 and 2,
respectively:
c1 = c
0
1, −L1 ≤ x ≤ 0, t = 0,
c2 = c
0
2, 0 < x ≤ L2, t = 0. (2.7)
The case of a single layer can easily be recovered, as will be demonstrated in Section 4.
2.1 Non-dimensionalisation
We now proceed to non-dimensionalise equations (2.1)-(2.7). We choose
x′ = x/L, t′ = De1t/φ1L
2, c′1 = c1/c
0
1, c
′
2 = c2/c
0
1.
The non-dimensionalised equations (after dropping primes) are then:
∂c1
∂t
=
∂2c1
∂x2
, −δ < x < 0, t > 0, (2.8)
∂c2
∂t
=
χ
φ
∂2c2
∂x2
, 0 < x < 1− δ, t > 0, (2.9)
−
∂c1
∂x
= Γ1c1, x = −δ, t > 0, (2.10)
−
∂c1
∂x
= Π(c1 − c2), x = 0, t > 0, (2.11)
∂c1
∂x
= χ
∂c2
∂x
, x = 0, t > 0, (2.12)
−χ
∂c2
∂x
= Γ2c2, x = 1− δ, t > 0, (2.13)
c1 = 1, −δ ≤ x ≤ 0, t = 0.
c2 = C
0, 0 < x ≤ 1− δ, t = 0. (2.14)
where
δ =
L1
L
, χ =
De2
De1
, C0 =
c02
c01
, φ =
φ2
φ1
, Π =
PL
De1
, Γ1 =
K1L
De1
, Γ2 =
K2L
De1
.
We note that the non-dimensional parameter χ contains all the important microstructural param-
eters which influence drug release.
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3 Solution procedure
3.1 Solution by Separation of Variables
The model given by (2.8)-(2.14) is amenable to solution by separation of variables, an approach
we have adopted in previous work considering two-layer and multi-layer problems [18, 17]. We let
c1(x, t) = X1(x)G1(t), c2(x, t) = X2(x)G2(t). (3.1)
Equations (2.8)–(2.9) give rise to the ordinary differential equations (ODEs):
G′1
G1
= −λ21,
φ
χ
G′2
G2
= −λ22, (3.2)
which yield the solution:
G1(t) = exp(−λ
2
1t), G2(t) = exp
(
−
χ
φ
λ22t
)
, (3.3)
and the Sturm-Liouville eigenvalue system:
X ′′1 = −λ
2
1X1, −δ < x < 0, (3.4)
−X ′1 = Γ1X1, x = −δ, (3.5)
X ′1 = χX
′
2, x = 0, (3.6)
X ′′2 = −λ
2
2X2, 0 < x < 1− δ, (3.7)
−χX ′2 = Γ2X2, x = 1− δ, (3.8)
−X ′1 = Π(X1 −X2), x = 0, (3.9)
obtained by setting G1 = G2, which implies
λ1 =
√
χ
φ
λ2. (3.10)
The general solution of the ODEs (3.4) and (3.7) is:
X1(x) = a1 cos(λ1x) + b1 sin(λ1x), X2(x) = a2 cos(λ2x) + b2 sin(λ2x), (3.11)
where the eigenvalues λi (i = 1, 2) and the unknown coefficients ai and bi may be computed by
imposing the boundary and interface conditions as follows. From equations (3.5) and (3.8), we have:
a1(λ1 sin(λ1δ) + Γ1 cos(λ1δ)) + b1(λ1 cos(λ1δ) − Γ1 sin(λ1δ)) = 0,
(3.12)
a2[−χλ2 sin(λ2(1− δ)) + Γ2 cos(λ2(1− δ))] + b2[χλ2 cos(λ2(1− δ)) + Γ2 sin(λ2(1− δ))] = 0.
(3.13)
From the interface conditions (3.6) and (3.9), it follows:
b1 λ1 = χ λ2 b2, (3.14)
−b1λ1 = Π(a1 − a2). (3.15)
Equations (3.12)–(3.15) form a system of four homogeneous linear algebraic equations in the
four unknowns a1, b1, a2 and b2 . To obtain a solution different from the trivial one (0, 0, 0, 0), it is
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necessary that the determinant of the coefficient matrix associated with the above system is equal
to zero, that is:
ϕ(λ1, λ2) =
(
λ1 sin(λ1δ) + Γ1 cos(λ1δ)
) [
Π
(
χλ2 cos(λ2(1− δ))+
Γ2 sin(λ2(1− δ))
)
+ χλ2
(
− χλ2 sin(λ2(1− δ)) + Γ2 cos(λ2(1− δ))
)]
−
Π
√
χφ
(
λ1 cos(λ1δ) − Γ1 sin(λ1δ)
)(
− χλ2 sin(λ2(1− δ)) + Γ2 cos(λ2(1− δ))
)
= 0 (3.16)
By replacing λ1 with λ2 through the relation (3.10), if the above transcendental equation (eigen
condition) in λ2 is satisfied, the coefficients may be taken as:
a2 =
χλ2 + Γ2 tan(λ2(1− δ))
−Γ2 + χλ2 tan(λ2(1− δ))
b2, (3.17)
a1 = a2 −
χ
Π
λ2 b2, (3.18)
b1 =
√
χ φ b2, (3.19)
where the multiplicative constant b2 is arbitrary and its value depends on the initial condition (see
below). We note that ϕ depends on the parameters Π, δ, χ, φ,Γ1,Γ2 (but not C0) and has infinitely
many roots (eigenvalues), which are real and distinct.
For each eigenvalue couple (λ1m, λ2m), m = 0, 1, 2, ..., satisfying (3.16), the constants a1m,
b1m and a2m are obtained from (3.18), (3.19) and (3.17) respectively, and thus the corresponding
eigenfunctions X1m and X2m defined in (3.11) are computed as:
X1m = b2mX˜1m = b2m
[
a˜1m cos(λ1mx) + b˜1m sin(λ1mx)
]
, (3.20)
X2m = b2mX˜2m = b2m [a˜2m cos(λ2mx) + sin(λ2mx)] , (3.21)
where the tilde indicates a variable which has been scaled by b2m.
Furthermore, the corresponding time-variable functions G1m and G2m defined by equations (3.3)
are computed as:
G1m = exp(−λ
2
1mt), G2m = exp
(
−
χ
φ
λ22mt
)
. (3.22)
(G1m = G2m). Finally, the complete solution of the problem is given by a linear superposition of
the fundamental solutions (3.1) in the form:
c1(x, t) =
∞∑
m=1
AmX˜1m(x) exp(−λ
2
1mt),
c2(x, t) =
∞∑
m=1
AmX˜2m(x) exp
(
−
χ
φ
λ22mt
)
, (3.23)
where the arbitrary constants Am(= b2m) are determined through the initial conditions (2.14).
The damping factors exp(−λ21mt) and exp
(
−
χ
φ
λ22mt
)
, m = 1, 2, ..., measure the attenuation of the
various terms in summations (3.23). Because of the fast exponential convergence, the series (3.23)
will be truncated at a finite number of terms, in accordance with the accuracy desired at the time
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of interest. Since maxx |AmX˜im(x)| < 1 for any i = 1, 2, m > 1, to reach an accuracy of 10−r, it is
sufficient to consider a finite series summation up to the index j > 1 such that
λ1j >
√
r ln 10
t
and the series is truncated at the first j terms. A value of j = 30 is considered for all times in the
simulations.
Application of the initial condition
By evaluating (3.23) at t = 0 and multiplying it by X˜1n, X˜2n, after integration we obtain:
0∫
−δ
∑
AmX˜1mX˜1n dx =
0∫
−δ
X˜1n dx, n = 1, 2, ..., (3.24)
and
1−δ∫
0
∑
AmX˜2mX˜2n dx = C
0
1−δ∫
0
X˜2n dx, n = 1, 2, ... (3.25)
By combining equations (3.24) and (3.25) and by using the orthogonality property of (X1m,X2m)
[18] :
Am


0∫
−δ
X˜21m dx+ φ
1−δ∫
0
X˜22m dx

 =
0∫
−δ
X˜1m dx+ φC
0
1−δ∫
0
X˜2m dx, (3.26)
we have:
Am =
0∫
−δ
X˜1m dx+ φC0
1−δ∫
0
X˜2m dx
0∫
−δ
X˜21m dx+ φ
1−δ∫
0
X˜22m dx
. (3.27)
3.2 Computing Mass
The total mass of drug at any time can be evaluated by integrating the drug concentrations in
each layer over their respective spatial domain. If we normalize the total mass by its initial value,
then the non-dimensional total mass of drug in the coating is given by
M(t) =
1
δ + (1− δ)φC0


0∫
−δ
c1(x, t)dx+ φ
1−δ∫
0
c2(x, t)dx

 . (3.28)
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Letting θi represent the non-dimensional mass of drug in each layer as a fraction of the total mass,
we then have:
θ1(t) =
1
δ + (1− δ)φC0
0∫
−δ
c1(x, t)dx
=
1
δ + (1− δ)φC0
∞∑
m=1
Am
(
a1m sin(λ1mδ) + b1m cos(λ1mδ)− b1m
λ1m
)
exp(−λ21mt), (3.29)
θ2(t) =
φ
δ + (1− δ)φC0
1−δ∫
0
c2(x, t)dx
=
φ
δ + (1− δ)φC0
∞∑
m=1
Am
(
a2m sin(λ2m(1− δ))− cos(λ2m(1− δ)) + 1
λ2m
)
exp
(
−
χ
φ
λ22mt
)
(3.30)
where ci (i = 1, 2) are given by (3.23). It is then straightforward to evaluate the total non-
dimensional mass of drug in the coating asM = θ1+θ2 and the cumulative fraction of drug release,
Mfrac (the release profile) as Mfrac = 1− (θ1 + θ2).
The depletion of the drug in coating as a result of the release process is governed by an expo-
nential decay as in the above equations. The analytical solution indicates that a complete release
is reached only asymptotically and equations (3.29)–(3.30) allow one to estimate the release time
Tr, within a given tolerance ǫ, through:
θ1(Tr) + θ2(Tr) ≤ ǫ.
The smallest eigenvalue λmin1 =
√
χ
φ
λmin2 relates to the dominant damping factor in the series (3.23),
(3.29)-(3.30). Comparing λmin1 between different parameter regimes provides an indication of the
relative rate of release (see Table 2). For the particular parameter regime of interest and a given
initial mass per cross-sectional area M0, the initial loading concentrations are calculated through:
c01 =
M0
Lφ1 (δ + φC0 (1− δ))
c02 = c
0
1C
0. (3.31)
3.3 Special Case
We note that in the special case where the microstructural properties of the layers are identical
(χ = φ = 1) then we can obtain an analytical solution. In this case, the eigenvalues λ1 = λ2 = λ,
say, and are obtained by solving
cos (λ) = 0.
The difference between the solutions c1 and c2 then arises only through Am, which is calculated
using the initial condition. It can be shown that the solution in this case is
c(x, t) =
4
π
∞∑
n=1
(−1)n cos
(
pi(2n−1)(x+δ)
2
){
(−1)n+1 sin
(
pi(2n−1)δ
2
) (
C0 − 1
)
− C0
}
exp
(
−pi
2(2n−1)2t
4
)
2n− 1
,
−δ < x < 1− δ,
(3.32)
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and the release profile is readily computed as:
Mfrac = 1 +
8
π2 (δ + (1− δ)C0)
∞∑
n=1
{
(−1)n+1 sin
(
pi(2n−1)δ
2
) (
C0 − 1
)
− C0
}
exp
(
−pi
2(2n−1)2t
4
)
(2n − 1)2
.
(3.33)
4 Results and Discussion
In all simulations, we consider the typical boundary conditions Γ1 = 0 and Γ2 →∞. This situa-
tion is representative of the most common case where the coating is in contact with an impermeable
material (e.g. metal structure of the device) on one side and is exposed to an infinite sink at the
other side, where the drug is washed away instantaneously. It is usual for infinite sink conditions
to be maintained during in-vitro drug release experiments. At the interface between the two layers,
we choose Π→∞ to reflect ‘unhindered’ transport.
The free diffusion coefficient of molecules in liquids Dw is typically of the order of 10−9 m2 s−1
[16]. By definition, 0 < φei < 1. However, extremely low (φ
e
i < 0.1) and extremely high (φ
e
i > 0.9)
porosities would likely result in drug loading and mechanical constraints, respectively. A typical
range of tortuosity values is 1 < τi < 6, although values as high as 10 have been reported [16]. Taken
together, we expect that the effect of the microstructure in each layer is to result in an effective
diffusion coefficient at most two orders of magnitude smaller than the free diffusion coefficient in
water. We note that drug diffusion coefficients in some polymers have been reported to be as low
as 10−17 m2 s−1. However, it should be noted that these are usually apparent diffusion coefficients
which likely incorporate other effects such as absorption and desorption (possibly in addition to
the microstructure effects that we consider here). The effect of such processes can be to reduce the
overall diffusion coefficient by several orders of magnitude. In all simulations we fix De1 = 5 · 10
−11
and φ1 = 0.6 and consider the effects of varying the microstructure of each layer by varying φ and
χ.
Since the purpose of this study is to establish the benefits of replacing a single layer with a
two-layer coating of identical total thickness L and initial drug mass, we fix L = 10−4m in all
simulations. In reality, of course, the values of De1, φ1 and L will vary depending on the particular
application. Since our focus is to investigate the effect of the results on varying the ratio between
the parameters of each layer, we have decided to choose broadly typical values, whilst acknowledging
that this will not cover all cases. In all of our simulations the initial non-dimensional mass is 1. We
choose not to mathematically implement a fixed dimensional mass. As a consequence, the initial
dimensional loading concentrations c01 and c
0
2 are to be back-calculated using (3.31) such that the
desired initial dimensional mass is achieved.
4.1 Baseline model
To assess the effect on drug release of variations in system parameters, we preliminarily assume
that layer 1 and layer 2 have identical microstructural parameters (χ = φ = 1) and equal initial
drug concentrations (C0 = 1): in this case we can use the analytical solutions given by (3.32-3.33).
The result is that our baseline model (see Table 1) essentially reduces to a single layer system
(the solution is independent of the choice of δ). The resulting non-dimensional parameters are
χ = φ = C0 = 1.
In Figure 4 we display the results of the baseline case, where each layer has identical initial drug
loading and microstructure, so that we effectively have a single layer. As a result of the infinite
10
Parameter Value (layer 1 − layer 2)
Dei (m
2s−1) 5 · 10−11 − 5 · 10−11
Li(m) 5 · 10
−5
− 5 · 10−5
φi 0.6 − 0.6
Ki 0 − 10
10(∗)
P (ms−1) 1010(∗)
Table 1: Reference dimensional parameter values used in the baseline simulations. The two layers
have the same physical parameters and unhindered transport between the layers, and so they are
equivalent to one layer. (∗) In reality, we wish to impose K2, P →∞, however, for the purposes of
the numerical simulations it was found that the value 1010 was sufficient to represent this case.
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Figure 4: Baseline case: the non-dimensional concentration profiles at three times and percentage of
drug mass released versus time (one layer, Table 1). Because of the perfect contact at the interface
(Π → ∞), the concentration curves results are insensitive to the location of the interface (left).
The mass percentages in the individual layers do vary with δ, but the release curves (green) do not
(right).
sink boundary condition at the release medium, drug is rapidly released from layer 2 in the early
stages, whilst there is a small delay before drug concentrations in layer 1 drop from their initial
value. Drug release from layer 1 proceeds at a slower rate than in layer 2, and therefore there is
a difference in both the shape and the duration of release in each layer. All of the drug has been
released from the system by approximately t = 3 (non-dimensional time).
4.2 Sensitivity analysis
We are ultimately interested in quantifying the effect on drug release of having two separate
layers (as opposed to a single layer) with different microstructure and drug loading parameters.
Therefore, it is of interest to vary the parameters, one at a time, around the baseline values and to
compare the resulting drug release profiles. We consider three cases (see Table 2): in Study 1 we
assess the effect of varying χ, whilst in Study 2 and Study 3 we vary C0 and φ, respectively. In
each case we consider three values of δ.
Study 1: effect of varying microstructure ratio χ
We now assess the effect of varying the relative microstructural parameters between the two
layers. In Figure 5, left column, we choose χ such that the effective diffusion coefficient in layer 2 is
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Study χ C0 φ λmin1 (δ = 0.5)
Baseline 1 1 1 1.57
0.5 1 1 1.16
1 2 1 1 2.03
1 0 1 1.57
2 1 5 1 1.57
1 1 2/3 1.61
3 1 1 3/2 1.50
Table 2: Range of non-dimensional parameters simulated. In each Study, three values of
δ(0.2, 0.5, 0.8) were used. λmin1 is an indicator of the release time.
half that of layer 1, whilst in the right column the effective diffusion coefficient is 2 times greater.
In the first case we observe that drug release from layer 1 is hindered by the lower effective diffusion
coefficient in layer 2 and as a result there is a delay in drug being released from layer 1. Despite
the lower effective diffusion coefficient in layer 2, there is still a burst release as a result of the
infinite sink conditions, but this effect is smaller than the baseline case. In the second case, the
faster effective diffusivity in layer 2 results not only in significantly faster drug release from layer
2, but also from layer 1 (Figure 5, right). In Figure 6 we plot the overall release profiles in these
two cases and compare with the baseline (dashed red line). We display only the case of δ = 0.5.
From Figure 6 we conclude that the parameter χ has a strong influence on both the shape (rate of
release) and the duration of release. This is perhaps unsurprising since χ appears prominently in
the exponential damping factor (see (3.23) and (3.30)). For χ = 0.5 and χ = 2 we observe faster
release and slower release, respectively, as we increase δ (not shown).
The implication here is that, simply by varying the microstructure of the two layers, not only
it is possible to alter the shape of the release profile, but it is also possible to ensure that drug is
delivered over some defined period of time. We note that although χ contains parameters relating
to both the porosity and tortuosity of each layer, it is the combination of these values (rather than
their individual size) which defines the release profile. For example, a value of χ = 2 could be
obtained by doubling the effective porosity of layer 2 (in comparison with layer 1) or, by doubling
the tortuosity of layer 1 (in comparison with layer 2). Therefore, this parameter is highly important
as it offers much flexibility from the manufacturing point of view.
Study 2: effect of varying ratio of initial concentrations C0
We now elucidate the effect of varying the initial drug concentration between the two layers. In
the first case (Figure 7, left) we choose the initial drug concentration in layer 2 to be zero, whilst
in the second case (Figure 7, right) we choose the concentration in layer 2 to be five times that of
layer 1. In the first case we observe that layer 2 is initially rapidly infiltrated with drug, before
drug is subsequently released after it has traversed the thickness of the second layer. In the second
case we observe that whilst layer 2 is depleted rapidly as a result of the infinite sink condition, at
early times an increase in drug concentration (and consequently drug mass) is observed in layer 1
due to the concentration gradient between the two layers (we are assuming that no drug can diffuse
between the layers prior to the coating being placed in the release medium). As layer 2 continues
to be depleted of drug, eventually the concentration gradient at the interface changes direction and
drug then diffuses from layer 1 into layer 2 before being released. In each case, the value of δ has a
significant impact on the concentration profile in each layer.
In Figure 8 we plot the overall release profiles in these two cases with δ = 0.5 and compare
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Figure 5: Non-dimensional concentration profiles for three layer thickness ratios δ, with χ = 0.5
(left) and χ = 2 (right), and the other parameters as in Table 2 (Study 1).
with the baseline (dashed red line). For both C0 = 0 and C0 = 5 we observe faster release as we
increase δ (not shown). We conclude that having a drug-free second layer can delay the start of
the drug-release process, which may be desirable in certain applications. In contrast, choosing a
higher initial drug concentration in the second layer can result in a larger burst of drug which also
may be advantageous in other circumstances. However, in all cases the overall duration of release
results the same. Therefore, the non-dimensional parameter C0 can be used as a tuning parameter
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Figure 6: Comparison of release profiles at three values of χ (all the other values as in table 2 and
δ = 0.5).
to vary the proportion of drug delivered in the initial stages. The inflection point at t = 0 (Figure
8, C0 = 0 - black curve) indicates a retardation time due to the filling of the second layer which is
initially empty.
Study 3: effect of varying porosity ratio φ
By varying φ from 2/3 to 3/2, no significant differences are found between the concentration profiles
(not shown). The release profiles are vitually indistinguishable for high values of δ, although minor
differences in the profiles are observed as δ is reduced (not shown). These results reinforce the idea
that it is the effective porosity in each layer φei that drives the drug release, rather than the overall
porosity φi.
Having studied separately the influence of the individual parameters, we note that a combination
of the above cases should be considered in order to meet the precise manufacturing requirements
or with the aim of optimising some quantity. For example, if the objective is to slow down the
release, then it appears that the simultaneous occurrence of the two cases χ < 1, C0 = 0 will boost
this property: in particular, a configuration with a lower effective porosity in layer 2 faced with
one of higher effective porosity in layer 1 acts more favourably to achieve this goal: the time scale
for release from layer 2 is increased, and layer 1 acts as a reservoir that continuously supplies drug
during elution.
5 Conclusions
In this paper we have presented a mathematical model of drug diffusion through two adjacent
porous layers and we have carried out a systematic study of the effect on drug release of changes
to system parameters. Our results indicate that the contrast in properties of the two layers can be
used as a means of better controlling the release, and that the quantity of drug delivered in the
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Figure 7: Non-dimensional concentration profiles for three layer thickness ratios δ, with C0 = 0
(left) and C0 = 5 (right) and the other parameters as in Table 2 (Study 2). The dimensional values
may be back-calculated from (3.31).
early stages can be modulated by varying the distribution of drug across the layers. We conclude
that microstructural and loading differences between variable porosity coating layers can be utilized
to tune the properties of the coating materials to obtain the desired drug release profile for a given
application. We expect that our results will generalise to the multi-layer case, with increasing
numbers of layers exhibiting contrasting properties potentially providing additional flexibility for
15
0 1 2 3 4 5
0
10
20
30
40
50
60
70
80
90
100
time
%
 o
f m
as
s r
el
ea
se
d
C0=0
C0=1
C0=5
Figure 8: Comparison of release profiles at three values of C0 (all the other values as in Table 2
and δ = 0.5).
targeting a specific release profile. Finally, as we reduce the thickness of each layer, in the limit we
can obtain a continuously changing porosity. Whilst we acknowledge that this may provide even
more flexibility in terms of controlling the release, the model we consider is a useful starting point
to assess the effect of variable porosity. Additionally, the manufacturing of such a system is likely
to be very challenging given the typical coating thicknesses.
We would like to emphasise that we have made a number of simplifications in this work. Perhaps
the most significant is the assumption that drug is transported via a diffusive mechanism only.
Depending on the particular coating material under consideration, it may be more appropriate to
account for: polymer-drug interactions; diffusion through the solid phase; erosion; swelling and/or
degradation. Additionally, in cases where fluid penetration into the coating is slow and/or the drug
in question is poorly soluble, then the model may need to account for the drug dissolution process.
Nevertheless, the model we have provided here will be relevant in a number of drug delivery cases.
Now that we have established that variable porosity coatings for drug-eluting devices are worth
further consideration, we will seek to study some of these additional features in future work.
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